关于B型肝炎病毒核心蛋白质全调节剂的专利审查 (2019年至今)
Shuo Wang1, Feiyue Ma1, Kai Tang1
1Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, PR China.
Expert opinion on therapeutic patents
|February 22, 2025
概括
新型乙型肝炎病毒 (HBV) 核心蛋白质全调节剂 (CpAMs) 是由于缺乏药理动力学和肝毒性问题而需要的. 本综述分析了最近的专利,以指导改进CPAM的开发.
科学领域:
- 乙型肝炎病毒 (HBV) 研究
- 药物的发现和开发.
- 药品化学 药品化学 是一个
背景情况:
- 肝炎病毒核心蛋白质是抗病毒疗法的关键标.
- 现有的HBV核心蛋白质全调节剂 (CpAMs) 面临着药物动力学 (PK) 和肝毒性差等挑战,阻碍了临床批准.
- 对于具有更好的安全性和有效性概况的新型CpAMs有着至关重要的需求.
研究的目的:
- 从2019年到现在对CPAM进行全面的专利分析.
- 在最近的专利文献中概述CpAMs的化学演变.
- 确定开发下一代CpAM的模式和原则.
主要方法:
- 对专利数据库 (EPO,CNIPA,USPTO) 的系统审查.
- 使用PubMed搜索相关研究文章的文献搜索.
- 专利CPAM的结构特征和化学演变的分析.
主要成果:
- 在过去的五年中,许多结构多样化的CPAM已经获得了专利.
- 观察到平衡活动,药物耐药性和耐药性的挑战.
- 确定推动改善药理动力学 (PD) 和药理学 (PK) 概况的关键结构模式.
结论:
- 了解化学进化对于克服当前CPAM开发的局限性至关重要.
- 对专利趋势的分析可以指导设计更有效,更安全的HBV治疗方法.
- 本综述为发现具有增强药物样性质的下一代CPAM提供了洞察力.
相关概念视频
Allosteric Regulation
57.5K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.5K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
Allosteric Proteins-ATCase
5.6K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K
Ligand Binding and Linkage
4.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K


